Description

Ubichinon compositum (acidum acetylsalicylicum) solution for injection 2.2 ml vials №5

Ingredients

Ubichinon compositum contains a combination of ubidecarenone (coenzyme Q10) and acetylsalicylic acid in a solution for injection.

Dosage

The recommended dosage is determined by a healthcare provider based on the individual’s condition. It is typically administered via intramuscular or intravenous injection.

Indications

Ubichinon compositum is indicated for use in conditions where coenzyme Q10 deficiency or aspirin therapy is required.

Contraindications

Do not use Ubichinon compositum if you are allergic to any of the ingredients, have a history of aspirin sensitivity, or are pregnant without medical advice.

Directions

Follow the instructions provided by your healthcare provider for the correct administration of Ubichinon compositum. Do not self-administer without proper medical guidance.

Scientific Evidence

Studies have shown that coenzyme Q10 supplementation can have beneficial effects on various health conditions, including cardiovascular health and mitochondrial function. The addition of acetylsalicylic acid in this formulation may provide additional benefits in certain patient populations.

Additional Information

Ubichinon compositum is a unique formulation that combines the benefits of coenzyme Q10 and acetylsalicylic acid in an injectable solution. This delivery method ensures rapid absorption and bioavailability of the active ingredients, making it suitable for patients who may have difficulty taking oral medications.

Pharmacological Effects

Coenzyme Q10 plays a crucial role in the electron transport chain and energy production within cells. Acetylsalicylic acid, on the other hand, is a nonsteroidal anti-inflammatory drug with antiplatelet effects. The combination of these two compounds in Ubichinon compositum may offer synergistic benefits in certain medical conditions.

Clinical Trials and Comparative Effectiveness

Clinical trials evaluating the efficacy of Ubichinon compositum in various patient populations are ongoing. Comparative studies against similar drugs are limited due to the unique combination of ingredients in this formulation. However, preliminary data suggest promising results in terms of cardiovascular protection and mitochondrial support.

For more information on the pharmacological effects and clinical trials of Ubichinon compositum, consult with your healthcare provider or refer to the latest research publications in the field.